Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -19.57 Million AUD | -34.07% |
| 2023 | -14.59 Million AUD | -3.46% |
| 2022 | -15.48 Million AUD | -23.38% |
| 2021 | -15.15 Million AUD | -40.09% |
| 2020 | -13.9 Million AUD | 18.78% |
| 2019 | -12.76 Million AUD | -19.62% |
| 2018 | -8.17 Million AUD | -77.96% |
| 2017 | -6.86 Million AUD | 35.09% |
| 2016 | -8.56 Million AUD | 13.2% |
| 2015 | -10.57 Million AUD | 15.61% |
| 2014 | -12.53 Million AUD | -58.87% |
| 2013 | -7.74 Million AUD | -2.18% |
| 2012 | -5.2 Million AUD | -23.67% |
| 2011 | -6.24 Million AUD | -28.44% |
| 2010 | -4.87 Million AUD | 46.13% |
| 2009 | -8.25 Million AUD | 23.9% |
| 2008 | -12.68 Million AUD | -9.92% |
| 2007 | -10.93 Million AUD | 1.82% |
| 2006 | -12.12 Million AUD | -701.51% |
| 2005 | -15.49 Million AUD | 126.98% |
| 2004 | -7.7 Million AUD | -269.48% |
| 2003 | -2.61 Million AUD | 45.8% |
| 2002 | -3.83 Million AUD | -81.62% |
| 2001 | -1.86 Million AUD | -442.06% |
| 2000 | -343.17 Thousand AUD | -328.97% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.44 Million AUD | 0.0% |
| 2024 Q1 | -3.3 Million AUD | -6.03% |
| 2024 FY | - AUD | -27.43% |
| 2024 Q4 | -15.02 Million AUD | 0.0% |
| 2024 Q3 | -6.48 Million AUD | -96.37% |
| 2023 Q4 | -7.72 Million AUD | -147.93% |
| 2023 Q3 | -3.11 Million AUD | 70.89% |
| 2023 FY | - AUD | -3.46% |
| 2023 Q1 | -4.18 Million AUD | 59.91% |
| 2023 Q2 | -10.69 Million AUD | -155.68% |
| 2022 Q2 | -10.13 Million AUD | -159.86% |
| 2022 Q4 | -10.43 Million AUD | -171.61% |
| 2022 Q3 | -3.84 Million AUD | 62.06% |
| 2022 Q1 | -3.89 Million AUD | 60.36% |
| 2022 FY | - AUD | -23.38% |
| 2021 Q1 | -3.87 Million AUD | 37.87% |
| 2021 Q3 | -4.2 Million AUD | 56.19% |
| 2021 FY | - AUD | -40.09% |
| 2021 Q4 | -9.83 Million AUD | -133.76% |
| 2021 Q2 | -9.6 Million AUD | -148.03% |
| 2020 FY | - AUD | 18.78% |
| 2020 Q4 | -6.23 Million AUD | -53.22% |
| 2020 Q1 | -2.88 Million AUD | 75.22% |
| 2020 Q2 | -7.54 Million AUD | -161.45% |
| 2020 Q3 | -4.06 Million AUD | 46.05% |
| 2019 Q3 | -3.58 Million AUD | -28.32% |
| 2019 Q4 | -11.63 Million AUD | -224.43% |
| 2019 FY | - AUD | -19.62% |
| 2019 Q2 | -2.79 Million AUD | -0.0% |
| 2019 Q1 | -2.79 Million AUD | -8.0% |
| 2018 FY | - AUD | -77.96% |
| 2018 Q1 | -1.49 Million AUD | -10.06% |
| 2018 Q4 | -2.58 Million AUD | 0.0% |
| 2018 Q3 | -2.58 Million AUD | -72.73% |
| 2018 Q2 | -1.49 Million AUD | -0.0% |
| 2017 Q2 | -2.06 Million AUD | 0.0% |
| 2017 FY | - AUD | 35.09% |
| 2017 Q4 | -1.36 Million AUD | 0.0% |
| 2017 Q3 | -1.36 Million AUD | 34.18% |
| 2017 Q1 | -2.06 Million AUD | 6.04% |
| 2016 Q3 | -2.2 Million AUD | -5.83% |
| 2016 Q2 | -2.08 Million AUD | 0.0% |
| 2016 Q1 | -2.08 Million AUD | 31.45% |
| 2016 Q4 | -2.2 Million AUD | 0.0% |
| 2016 FY | - AUD | 13.2% |
| 2015 FY | - AUD | 15.61% |
| 2015 Q3 | -3.03 Million AUD | -34.72% |
| 2015 Q4 | -3.03 Million AUD | 0.0% |
| 2015 Q2 | -2.25 Million AUD | 0.0% |
| 2015 Q1 | -2.25 Million AUD | 3.62% |
| 2014 Q2 | -3.91 Million AUD | -0.0% |
| 2014 Q4 | -2.33 Million AUD | 0.0% |
| 2014 FY | - AUD | -58.87% |
| 2014 Q3 | -2.33 Million AUD | 40.27% |
| 2014 Q1 | -3.91 Million AUD | -117.81% |
| 2013 Q3 | -1.79 Million AUD | 0.0% |
| 2013 FY | - AUD | -2.18% |
| 2013 Q4 | -1.79 Million AUD | 0.0% |
| 2012 FY | - AUD | -23.67% |
| 2011 FY | - AUD | -28.44% |
| 2010 FY | - AUD | 46.13% |
| 2009 FY | - AUD | 23.9% |
| 2008 Q2 | -2.37 Million AUD | -1973.46% |
| 2008 FY | - AUD | -9.92% |
| 2008 Q4 | -13.1 Million AUD | -11144.72% |
| 2008 Q3 | 118.66 Thousand AUD | 104.99% |
| 2008 Q1 | 127 Thousand AUD | 101.12% |
| 2007 FY | - AUD | 1.82% |
| 2007 Q4 | -11.36 Million AUD | -8504.24% |
| 2007 Q3 | 135.2 Thousand AUD | 103.86% |
| 2007 Q2 | -3.5 Million AUD | -3063.34% |
| 2007 Q1 | 118.3 Thousand AUD | 100.99% |
| 2006 Q2 | -2.81 Million AUD | -1393.69% |
| 2006 Q1 | 217.29 Thousand AUD | 101.57% |
| 2006 Q3 | 190.67 Thousand AUD | 106.78% |
| 2006 Q4 | -11.98 Million AUD | -6385.63% |
| 2006 FY | - AUD | -701.51% |
| 2005 Q2 | -1.1 Million AUD | -262.16% |
| 2005 FY | - AUD | 126.98% |
| 2005 Q1 | 684.35 Thousand AUD | 106.46% |
| 2005 Q4 | -13.82 Million AUD | -2270.86% |
| 2005 Q3 | 637 Thousand AUD | 157.4% |
| 2004 Q4 | -10.59 Million AUD | -1853.18% |
| 2004 FY | - AUD | -269.48% |
| 2004 Q1 | 561.87 Thousand AUD | 111.7% |
| 2004 Q2 | -1.65 Million AUD | -394.16% |
| 2004 Q3 | 604.41 Thousand AUD | 136.57% |
| 2003 FY | - AUD | 45.8% |
| 2003 Q2 | -1.27 Million AUD | -625.94% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q3 | 574.13 Thousand AUD | 145.03% |
| 2003 Q4 | -4.8 Million AUD | -936.43% |
| 2002 FY | - AUD | -81.62% |
| 2001 FY | - AUD | -442.06% |
| 2000 FY | - AUD | -328.97% |
| 1999 FY | - AUD | -11494.2% |
| 1998 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | -12.675% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -403.862% |
| CSL Limited | 4.78 Billion USD | 100.409% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 120.812% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1988.865% |
| BioStem Technologies, Inc. | -7.55 Million USD | -159.101% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1018.378% |
| Qrons Inc. | -40.08 Thousand USD | -48730.126% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3810.728% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 64.633% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -173.298% |
| Skye Bioscience, Inc. | -13.54 Million USD | -44.466% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -5229.652% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1958.002% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -23.327% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | 92.131% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2994.785% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 72.448% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -230.105% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -8083.819% |
| SQZ Biotechnologies Company | -64.14 Million USD | 69.487% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -640.102% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1174.152% |
| Mesoblast Limited | -62.38 Million USD | 68.63% |
| Marizyme, Inc. | -34.28 Million USD | 42.909% |
| Genus plc | 73.7 Million USD | 126.556% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -196.023% |
| Pharming Group N.V. | 9.87 Million USD | 298.153% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1215.816% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -451.779% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -123.114% |
| ContraFect Corporation | -64.99 Million USD | 69.889% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -332.407% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1296.169% |
| IMV Inc. | -35.52 Million USD | 44.905% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -742.217% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3677.966% |
| ONE Bio Corp. | 13.61 Million USD | 243.771% |
| Accustem Sciences Inc. | -3.74 Million USD | -422.408% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 59.418% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -1444.559% |
| Q BioMed Inc. | -617.62 Thousand USD | -3068.834% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 647.917% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -756.717% |
| Biomind Labs Inc. | -1.03 Million USD | -1791.8% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 50.623% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -576.673% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 291170.836% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -78186.412% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -682.25% |
| GB Sciences, Inc. | -1.41 Million USD | -1278.394% |
| Alpha Cognition Inc. | -9.7 Million USD | -101.653% |
| HST Global, Inc. | -5303.00 USD | -368966.623% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -851.463% |
| Halberd Corporation | -74.27 Thousand USD | -26248.77% |
| Enzolytics Inc. | -2.12 Million USD | -822.306% |
| Agentix Corp. | -1.37 Million USD | -1326.755% |
| Resverlogix Corp. | -11.74 Million USD | -66.68% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -538.965% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 90.94% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1708.184% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 321.053% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1205.726% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 5266.138% |
| AVAX Technologies, Inc. | -6.11 Million USD | -220.182% |
| Zenith Capital Corp. | -8.6 Million USD | -127.418% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -112244.888% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -699.997% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -11018.69% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -918.871% |
| Kadimastem Ltd | -2.62 Million USD | -645.761% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1770.532% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -10707.786% |
| LadRx Corporation | 412.28 Thousand USD | 4847.128% |
| Cell Source, Inc. | -4.27 Million USD | -358.08% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1435.074% |
| NovAccess Global Inc. | -1.03 Million USD | -1791.347% |
| Affymax, Inc. | -14.29 Million USD | -36.912% |
| Itoco Inc. | -1.86 Million USD | -947.173% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -5055.577% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1653.728% |
| Mobile Lads Corp. | -2.24 Million USD | -773.28% |
| CytoDyn Inc. | -18.02 Million USD | -8.556% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -24665.09% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -159942.546% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3929.749% |
| SYBLEU INC | -141.57 Thousand USD | -13724.585% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1742.883% |
| International Stem Cell Corporation | 202 Thousand USD | 9788.912% |
| Bioxytran, Inc. | -3.82 Million USD | -412.326% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -37080.097% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -694.969% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 45.436% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -43392.451% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -614.814% |
| Neutra Corp. | -181.24 Thousand USD | -10698.305% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 2.914% |
| PureTech Health plc | -11.62 Million USD | -68.329% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 2.907% |
| IXICO plc | -707 Thousand USD | -2668.261% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -154.673% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 59.518% |
| CSL Limited | 4.73 Billion USD | 100.414% |
| Cellectis S.A. | -92.63 Million USD | 78.873% |